RaeSedo

Executive Summary

RaeSedo Inc. is a San Diego-based biotechnology company pioneering a novel class of asthma therapeutics based on Surfactant Protein-A (SP-A). The company is developing small peptide mimetics of this endogenous lung protein to reduce inflammation, mucus, and airway constriction, aiming to create a replacement therapy for asthma patients with dysfunctional or deficient SP-A. Founded in 2001 and currently in the pre-clinical stage, RaeSedo addresses a significant unmet need in asthma treatment, as current therapies largely manage symptoms rather than targeting underlying deficiencies. The company's approach has the potential to offer a disease-modifying therapy for a subset of asthma patients. However, as a private, pre-revenue biotech without disclosed funding or valuation, the company faces substantial development and regulatory risks typical of early-stage therapeutics. Success hinges on advancing preclinical studies, attracting financing, and demonstrating proof-of-concept in vivo. Given the early stage, conviction is moderate, pending key milestones.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling studies40% success
• Q4 2026Series A financing round35% success
• Q3 2026Preclinical efficacy data in asthma models50% success